CVS HEALTH CORPORATION $750,000,000 3.625% Senior Notes due 2027 $1,500,000,000 3.750% Senior Notes due 2030 $1,000,000,000 4.125% Senior Notes due 2040 $750,000,000 4.250% Senior Notes due 2050 Underwriting AgreementSignificant Subsidiaries • March 31st, 2020 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York
CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $750,000,000 aggregate principal amount of its 3.625% Senior Notes due 2027 (the “2027 Notes”), $1,500,000,000 aggregate principal amount of its 3.750% Senior Notes due 2030 (the “2030 Notes”), $1,000,000,000 aggregate principal amount of its 4.125% Senior Notes due 2040 (the “2040 Notes”) and $750,000,000 aggregate principal amount of its 4.250% Senior Notes due 2050 (the “2050 Notes” and, together with the 2027 Notes, 2030 Notes and 2040 Notes, the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which Barclays Capital Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) be issued pursu
